CFDA approved the application for production registration of the Quadrivalent Influenza Vaccine produced by Hualan Biological Bacterin Co., Ltd.
Hualan Biological Bacterin Co., Ltd. obtained the approval document issued by the CFDA for the clinical trial of Adsorbed Hand-Foot-Mouth Disease ( EV71 ) Vaccine ( Vero Cells ), Inactivated.
Influenza Vaccine (Split, Virion), Quadrivalent developed by Hualan Bio has already applied for the production number and under review by Center for Drug Evaluation, CFDA currently.
The Quadrivalent Influenza Vaccine developed by the Hualan Bio this time contains the above two influenza A and two influenza B antigens, covering more influenza epidemic types, which will effectively prevent and control influenza epidemic.
Hualan Genetic Engineering Co. Ltd received the new drug application acceptance notice of " Recombinant Anti- CTLA-4 Human Monoclonal Antibody Injection" issued by China Food and Drug Administration.
Group AC Meningococcal Polysaccharide Vaccine of Hualan Biological Bacterin Co., Ltd Passing GMP
Shengming Bio is wholly owned subsidiary of Hualan Group and can provide CRO and CMO services related to monoclonal antibody drugs that fully meet the requirements of CFDA/FDA.
Hualan Bio, 2018 CSITF Exhibition, Biological Medicine, Plasma Products, Vaccine Products